Viatris (VTRS)
(Delayed Data from NSDQ)
$10.89 USD
-0.15 (-1.36%)
Updated Feb 4, 2025 04:00 PM ET
After-Market: $10.88 -0.01 (-0.09%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth B Momentum A VGM
Price, Consensus and EPS Surprise
VTRS 10.89 -0.15(-1.36%)
Will VTRS be a Portfolio Killer in February?
Zacks Investment Research is releasing its prediction for VTRS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VTRS
Is Viatris (VTRS) a Great Value Stock Right Now?
Theravance's Q3 Loss Narrower Than Expected, Revenues Rise Y/Y
VTRS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Viatris Beats on Q3 Earnings and Revenues, Lowers Profit Guidance
Viatris (VTRS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Viatris (VTRS) Beats Q3 Earnings and Revenue Estimates
Other News for VTRS
Viatris Inc (VTRS) Announces Upcoming Financial Results Release for Q4 and Full Year 2024
Current Report: Viatris Inc
Why Johnson & Johnson's Strong Buy Rating Is Justified (Rating Upgrade)
Viatris: Consolidate In 2025, Win In 2026 - How 'Phase 2' Of Business Plan May Play Out
Chris Davis Reduces Stake in Viatris Inc: A Strategic Portfolio Adjustment